Home » Stocks » RMD

ResMed Inc. (RMD)

Stock Price: $200.97 USD 0.88 (0.44%)
Updated Feb 24, 2021 4:00 PM EST - Market closed
After-hours: $200.20 -0.77 (-0.38%) Feb 24, 7:49 PM
Market Cap 29.24B
Revenue (ttm) 3.09B
Net Income (ttm) 698.86M
Shares Out 145.25M
EPS (ttm) 4.79
PE Ratio 41.96
Forward PE 40.98
Dividend $1.56
Dividend Yield 0.78%
Trading Day February 24
Last Price $200.97
Previous Close $200.09
Change ($) 0.88
Change (%) 0.44%
Day's Open 199.56
Day's Range 199.01 - 202.97
Day's Volume 433,545
52-Week Range 107.96 - 223.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 weeks ago

PAHC vs. RMD: Which Stock Is the Better Value Option?

Other stocks mentioned: PAHC
Zacks Investment Research - 3 weeks ago

ResMed (RMD) reported second-quarter fiscal 2021 revenues of $800 million, up 9% from a year ago.

Seeking Alpha - 3 weeks ago

ResMed Inc. (RMD) CEO Mick Farrell on Q2 2021 Results - Earnings Call Transcript

Zacks Investment Research - 3 weeks ago

ResMed (RMD) delivered earnings and revenue surprises of 15.57% and 3.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 3 weeks ago

Shares of ResMed (NYSE:RMD) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 16.53% year over year to $1.41, which beat the es...

Business Wire - 3 weeks ago

SAN DIEGO--(BUSINESS WIRE)--ResMed Inc. (NYSE: RMD, ASX: RMD), a world-leading digital health company, today announced results for its quarter ended December 31, 2020. Second Quarter 2021 High...

Benzinga - 4 weeks ago

On Thursday, January 28, ResMed (NYSE:RMD) will release its latest earnings report. Decipher the announcement with Benzinga's help.

Zacks Investment Research - 1 month ago

Telemedicine is here to stay as the new coronavirus strain triggers a fear psychosis at large, thereby retaining solid demand for telehealth stocks.

Other stocks mentioned: AMWL, TDOC, UNH
Zacks Investment Research - 1 month ago

QDEL vs. RMD: Which Stock Is the Better Value Option?

Other stocks mentioned: QDEL
Business Wire - 1 month ago

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind device to reduce the cost and complexity of dialysi...

Other stocks mentioned: OM
Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2021 on Thursday, January 2...

Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Ja...

Zacks Investment Research - 1 month ago

We have selected five MedTech growth stocks with further rooms for improvement in 2021.

Other stocks mentioned: DSRLF, HOLX, IDXX, OMI
Zacks Investment Research - 1 month ago

Investors continue to be optimistic about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.

Zacks Investment Research - 2 months ago

A steady sales growth is key to survival for any company. Let's check Broadcom (AVGO), PennyMac Financial (PFSI), ResMed (RMD) Williams-Sonoma (WSM) & Parker-Hannifin (PH) as these are likely ...

Other stocks mentioned: AVGO, PFSI, PH, WSM
Zacks Investment Research - 2 months ago

Here are a few stocks which are gaining from the booming digital healthcare space and are likely to maintain momentum in 2021, making them prudent investment choices.

Other stocks mentioned: NXGN, TDOC
Zacks Investment Research - 2 months ago

If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

Other stocks mentioned: LSTR, MAS, TTC
Zacks Investment Research - 2 months ago

Here are a few MedTech stocks which continued to outperform their respective industries amid the pandemic and can turn out to be wise investment choices.

Other stocks mentioned: HOLX, IDXX, TMO, WST
CNBC Television - 2 months ago

Final Trades: Home Depot, Zimmer Holdings, Tractor Supply & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other stocks mentioned: HD, TSCO, ZBH, UNFI
Business Wire - 2 months ago

SAN DIEGO--(BUSINESS WIRE)---- $TNDM--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Rajwant (Raj) Si...

Other stocks mentioned: TNDM
Zacks Investment Research - 2 months ago

Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.

Other stocks mentioned: APAM, LSTR, MAS
Zacks Investment Research - 2 months ago

Is (RMD) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 2 months ago

Investors continue to be positive about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.

CNBC Television - 3 months ago

ResMed CEO on digital health, treating patients outside the hospital

ResMed CEO Michael Farrell broke down how the medical equipment benefits from the emerging digital medicine space.

Zacks Investment Research - 3 months ago

If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

Other stocks mentioned: INTU, KLAC, MAS
Investors Business Daily - 3 months ago

Medical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.

Other stocks mentioned: ALGN, PODD, QDEL, RGEN
Zacks Investment Research - 3 months ago

3 Stocks to Capitalize on Promising Medical Products Industry

Other stocks mentioned: ABT, BAX
Zacks Investment Research - 3 months ago

Is (RMD) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 3 months ago

Dividend growth strategy is a major source of consistent income for investors in any type of market, though it doesn't offer dramatic price appreciation.

Other stocks mentioned: ATVI, BBY, MSFT, NSP
Business Wire - 3 months ago

NEW DELHI--(BUSINESS WIRE)---- $RMD #sleep--ResMed's #WakeUpToGoodSleep campaign highlights the growing and largely unidentified sleep disorders in India and the treatment options available.

Business Wire - 3 months ago

SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a virtual fireside chat at the Credit Suisse 29th Annual Glo...

Investors Business Daily - 3 months ago

ResMed shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. The post ResMed Shows Healthy Improvement Amid Top-Notch Profit Growth appeared first on Inves...

Zacks Investment Research - 3 months ago

ResMed's (RMD) overall increase in Q1 revenues is driven by robust performance of its mask and device product portfolios on increased demand for ventilators and ventilator masks.

Zacks Investment Research - 3 months ago

ResMed (RMD) delivered earnings and revenue surprises of 29.59% and 7.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 3 months ago

SAN DIEGO--(BUSINESS WIRE)--ResMed Inc. (NYSE: RMD, ASX: RMD), a world-leading digital health company, today announced results for its quarter ended September 30, 2020. First Quarter 2021 High...

Zacks Investment Research - 3 months ago

PAHC vs. RMD: Which Stock Is the Better Value Option?

Other stocks mentioned: PAHC
Zacks Investment Research - 3 months ago

ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 3 months ago

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research - 4 months ago

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GuruFocus - 4 months ago

In light of coronavirus cases increasing both domestically and internationally, four health care companies with strong business quality are Biogen Inc. (NASDAQ:BIIB), Novo Nordisk A/S (NYSE:NV...

Other stocks mentioned: BIIB, ILMN, NVO
Zacks Investment Research - 4 months ago

Here are three growth stocks from the MedTech space that investors can pick ahead of the quarterly releases.

Other stocks mentioned: IDXX, LHCG
Zacks Investment Research - 4 months ago

Grab these four stocks that continue to show tremendous promise despite market volatility resulting from the coronavirus pandemic.

Other stocks mentioned: DVA, LHCG, OMI
Zacks Investment Research - 4 months ago

Let's take a look at three large-cap MedTech stocks that are currently flourishing on the back of a number of positive developments.

Other stocks mentioned: LHCG, NVCR
Business Wire - 4 months ago

SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2021 on Thursday, October 29...

Zacks Investment Research - 4 months ago

Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.

Other stocks mentioned: DPZ, MTH, NRG, VRTX
GuruFocus - 4 months ago

As the world grapples with an unprecedented coronavirus pandemic, five health care stocks that have outperformed the Standard & Poor's 500 Index by at least 5% in the year to date are Amerisou...

Other stocks mentioned: ABC, CHE, NEOG, NVO
Zacks Investment Research - 5 months ago

Investors continue to be positive about ResMed (RMD) owing to its robust product line and consistent high demand for its critical care products.

Business Wire - 5 months ago

SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a virtual fireside chat at the Morgan Stanley 1...

PRNewsWire - 5 months ago

CAMBRIDGE, Mass., Sept. 9, 2020 /PRNewswire/ -- The MIT Leaders for Global Operations (LGO) program announced today that ResMed, a global digital health and connected medical device company, h...

Zacks Investment Research - 5 months ago

ResMed (RMD) reported earnings 30 days ago. What's next for the stock?

About RMD

ResMed develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnos... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Jun 2, 1995
CEO
Michael Farrell
Employees
7,770
Stock Exchange
NYSE
Ticker Symbol
RMD
Full Company Profile

Financial Performance

In 2020, ResMed's revenue was $2.96 billion, an increase of 13.44% compared to the previous year's $2.61 billion. Earnings were $621.67 million, an increase of 53.65%.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for ResMed stock is "Hold." The 12-month stock price forecast is 214.60, which is an increase of 6.78% from the latest price.

Price Target
$214.60
(6.78% upside)
Analyst Consensus: Hold